paroxetine / Generic mfg. - LARVOL DELTA

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study (ASH 2025) - "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."

Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease

The Comparative Efficacy of Antidepressant and Psychological Therapies on Cognition in Depression: A Systematic Review and Network Meta-Analysis. (PubMed, Neuropsychol Rev) - "Common antidepressants, including escitalopram, citalopram, paroxetine and fluoxetine were not significantly different from placebo in improving cognition. The findings suggest that, among antidepressants, vortioxetine is the sole treatment improving cognition in depression. The effects were however small, highlighting the need for the development of MDD interventions targeting cognition."

Journal • Retrospective data • Review • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The impact of antidepressant use on antibiotic treatment outcomes in urinary tract infections and pneumonia: A population-based cohort study. (PubMed, Psychiatry Clin Neurosci) - "Antidepressants are associated with a modest rise in UTI treatment failure risk, possibly due to antibiotic resistance or other mechanisms. Despite this, their essential role in mental health management outweighs the small risk, emphasizing the need for judicious use, particularly in females and older adults. Further research is warranted to clarify underlying mechanisms."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

G protein subtype preference dictates paroxetine-enhanced serotonin receptor response in non-malignant breast epithelial cells. (PubMed, Biochem Pharmacol) - "This matrix of interactions suggest that the anti-proliferative responses to 5-HT in non-malignant breast cells align with the G protein preference of the receptors. The potential benefits of repurposing receptor subtype-selective agents and SSRIs, and their ideal combinations, represent a novel opportunity for cancer risk reduction."

Journal • Breast Cancer • Oncology • Solid Tumor

Evaluation of the efficacy and safety of different doses of daily paroxetine in patients with lifelong premature ejaculation: a prospective randomized crossover study. (PubMed, Int Urol Nephrol) - "12.5 mg paroxetine may be preferentially prescribed over 20 mg as it shows a comparable efficacy with lower adverse events and subsequent better tolerability and male sexual QOL."

Journal • Sexual Disorders

Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention. (PubMed, Am J Hum Genet) - "Analyzing >3.5 million electronic health records, we conducted analyses of emulated trials for 11 drugs across 290 comparisons and identified three drugs significantly associated with reduced colorectal cancer risk: caffeine vs. paroxetine (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.41-0.64), haloperidol vs. prochlorperazine (HR, 0.47; 95% CI, 0.33-0.68), and trazodone hydrochloride vs. paroxetine (HR, 0.49; 95% CI, 0.38-0.63). Conversely, caffeine was associated with increased cancer risk in comparison with finasteride (colorectal cancer) and fluoxetine (breast cancer). Meta-analysis identified six drugs significantly associated with cancer risk, including acetazolamide, which was associated with reduced colorectal cancer risk (HR, 0.79; 95% CI, 0.72-0.87). This study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights several approved drugs with potential chemopreventive effects."

Biomarker • Journal • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Modified electroconvulsive therapy for severe malnutrition secondary to obsessive-compulsive disorder: A case report. (PubMed, PCN Rep) - "At the 10-month follow-up, she maintained a weight of 50.3 kg and a stable psychiatric status on paroxetine and CBT. mECT offers a rapid, effective intervention for treatment-refractory OCD complicated by critical malnutrition, achieving prompt symptom relief while simultaneously facilitating nutritional rehabilitation."

Journal • Anesthesia • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors. (PubMed, BMC Med) - "In this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • CNS Disorders • CYP3A4

Paroxetine-induced black hairy tongue and necrotizing sialometaplasia: a case report. (PubMed, J Med Case Rep) - "This case demonstrates the need to consider black hairy tongue and necrotizing sialometaplasia as differential diagnoses in patients with relevant risk factors presenting with oral lesions. Black hairy tongue and necrotizing sialometaplasia can both be managed conservatively by removal of the causative factor and maintaining good oral hygiene; nevertheless, timely and accurate diagnosis is important owing to the fact that necrotizing sialometaplasia may closely resemble more sinister pathology. Clinicians may also consider including black hairy tongue and necrotizing sialometaplasia as rare side effects of paroxetine when offering medication counseling."

Journal • Inflammation

Electroacupuncture improves post-traumatic stress disorder in rats by alleviating hippocampal mitochondrial injury via regulating Bcl-2/Bax/caspase-3 signaling (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "EA alleviates PTSD in rats possibly by upregulating Bcl-2 and downregulating Bax and caspase-3, thereby ameliorating hippocampal mitochondrial damage."

IO biomarker • Journal • Preclinical • CNS Disorders • Post-traumatic Stress Disorder • Psychiatry • BAX • BCL2 • CASP3

Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis. (PubMed, Transl Psychiatry) - "Commonly used antidepressants have different gastrointestinal effects. Duloxetine, levomilnacipran, and vilazodone carry a higher risk of inducing nausea and vomiting, whereas trazodone, amitriptyline, agomelatine, and mirtazapine tend to be better tolerated. Amitriptyline, clomipramine, and reboxetine are more prone to induce constipation. Diarrhoea is more commonly associated with vilazodone, fluvoxamine, and sertraline. Amitriptyline, reboxetine, and duloxetine are more likely to cause anorexia. Amitriptyline, reboxetine, and trazodone are related to causing dry mouth. Compared with the placebo, amitriptyline, fluoxetine, and paroxetine were associated with a greater incidence of dyspepsia."

Journal • Retrospective data • Review • Anorexia • CNS Disorders • Constipation • Depression • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry • Xerostomia

Pharmacologic Interventions for Symptomatic Treatment of Cough among Adults with Lung Malignancy: A Systematic Review and Meta-Analysis (APSR 2025) - "Results : Thirteen studies met the inclusion criteria and these examined the use of aprepitant (two), levodropropizine (three), opioid and its derivatives (six), paroxetine (one), and pregabalin (one). Aprepitant showed significant improvement in cough among lung cancer patients. Additional good quality trials are recommended to refine and expand current guideline recommendations."

Retrospective data • Review • Addiction (Opioid and Alcohol) • Cough • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM-I against influenza A Virus Infection. (PubMed, Adv Healthc Mater) - "Here, we evaluated inhibitors of G protein-coupled receptor kinases (GRKs; paroxetine, CMPD101) and protein kinase C (PKC; Gö6983, bisindolylmaleimide-I (BIM-I)) for anti-IAV activity...Confocal microscopy confirmed efficient uptake of all formulations, particularly PEGylated and PEtOxylated nanoparticles. These findings highlight nanoparticle-mediated delivery of BIM-I as a promising host-directed antiviral strategy against IAV and support PEtOx as a viable PEG alternative in nanomedicine."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Implementation of an easy and cost-effective method for POCIS in situ calibration using o-DGT for pharmaceutical compounds. (PubMed, Talanta) - "In the context of monitoring programs, deploying o-DGT during initial campaigns could facilitate Rs determination under specific environmental conditions, which can then be applied to subsequent campaigns. Nevertheless, for compounds with low affinity for o-DGT, as Paroxetine, the proposed method is limited to obtain robust Rs."

HEOR • Journal

Cutting Costs, Not Care: New Models for Affordable Men's Health Medications. (PubMed, Urology) - "CPDC provides significant cost savings on men's health medications compared to Medicare and GoodRx."

Journal • Benign Prostatic Hyperplasia • Erectile Dysfunction • Infertility • Sexual Disorders

Regional Effects of Citalopram on Motor Performance and L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease (Neuroscience 2025) - "Indeed, prior work has shown that selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine, and paroxetine attenuate AIMs when systemically co-administered with L-DOPA in animal models of PD. All animals were then rendered dyskinetic with 7 days of L-DOPA treatment (12 mg/kg; s.c.) Counterbalanced coadministration testing began on day 8 with L-DOPA (6 mg/kg; sc) and systemic (5 mg/kg, s.c.) or intracerebral citalopram (0, 3 or 10 µg) after which rats were evaluated for AIMs and motor efficacy. Preliminary results have supported the ability of citalopram to effectively reduce LID without sacrificing the motor benefits of L-DOPA though unique contributions to these effects have emerged in a region-dependent manner."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Chaihu-Jia-Longgu-Muli Decoction Improves Dizziness with Anxiety in Rats by Modulating Tryptophan Metabolism. (PubMed, J Ethnopharmacol) - "CLMD significantly promoted vestibular function recovery and alleviated anxiety symptoms by improving neuroplasticity, regulating metabolic pathways, and modulating inflammation, showing potential as a treatment for dizziness with anxiety."

Journal • Preclinical • CNS Disorders • Depression • Epilepsy • Inflammation • Insomnia • Mood Disorders • Otorhinolaryngology • Psychiatry • Sleep Disorder • IL1B • IL6

Studies Addressing Potential Bioactivation and Genotoxicity Liabilities of the N-Nitroso Derivative of the Antidepressant Paroxetine. (PubMed, Xenobiotica) - "Virtually all stable metabolites of N-nitrosoparoxetine in human, rat, and hamster liver tissue were derived from phase 2 conjugations on an unstable catechol intermediate, generated from the oxidative 1,3-benzodioxole ring scission by CYP enzymes. The piperidine ring in N-nitrosoparoxetine was resistant to the α-carbon oxidation step leading to piperidine ring scission, and to the eventual formation of a DNA-reactive electrophilic species.3.CYP reaction phenotyping studies demonstrated that paroxetine was exclusively metabolized by human CYP2D6, whereas N-nitrosoparoxetine was subject to metabolism by multiple human CYP isoforms including CYP2C19, CYP2D6, and CYP3A4.4.Whether most NDSRIs derived from parent amine precursors that are resistant to α-carbon oxidation by CYPs will also be devoid of a mutagenic response in vitro needs to be scrutinized further with additional examples to bolster structure-genotoxicity relationships of complex NDSRIs."

Journal • CYP2C19 • CYP3A4

Activation of GPR81 protects against myocardial ischemia-reperfusion injury under aberrant glucose metabolism condition by modulating VILIP-1/GRK2/GLUT4 pathway. (PubMed, Int J Biol Macromol) - "These protective effects were reversed upon inhibition of GPR81 using 3-hydroxy-butyrate (3-OBA) or GRK2 inhibition using paroxetine. Our findings suggest that GPR81 activation exerts a protective effect against myocardial I/R injury by enhancing glucose metabolism via the VILIP-1/GRK2/GLUT4 signaling axis."

Journal • Cardiovascular • Myocardial Ischemia • Reperfusion Injury • SLC2A4 • VSNL1

Exploratory Clinical Study on Drug Repurposing—Paroxetine Combined with Chemotherapy for the Treatment of Recurrent Ovarian Cancer (ChiCTR) - P4 | N=29 | Not yet recruiting | Sponsor: The International Peace Maternity and Child Health Hospital; The International Peace Maternity and Child Health Hospital

New P4 trial • Oncology • Ovarian Cancer • Solid Tumor • MUC16

The Clinical study of SWTX capsules in the treatment of depression (ChiCTR) - P=N/A | N=114 | Recruiting | Sponsor: Inner Mongolia Autonomous Region Mental Health Center.; Inner Mongolia Autonomous Region Mental Health Center.

New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

Pharmacogenetic Guidelines and Resources to Support Antidepressant and Antipsychotic Use in Child and Adolescent Psychiatry (AACAP 2025) - "The FDA categorizes drug-gene pairs by implications on therapeutic management, safety, or pharmacokinetics. If a patient has genotype results available, the CPIC and/or FDA currently provide assessments supporting the utility of PGx to inform the use of many antidepressants including es/citalopram (CYP2C19), fluvoxamine (CYP2D6), paroxetine (CYP2D6), sertraline (CYP2C19 and CYP2B6), TCAs (CYPC19 and/or CYP2D6), venlafaxine (CYP2D6), and vortioxetine (CYP2D6)...FDA labeling provides specific dosing based on CYP2D6 poor metabolizer genotypes for aripiprazole, brexpiprazole, iloperidone, pimozide, and thioridazine... CPIC and FDA resources are useful for identifying evidence-based PGx information for commonly used antidepressants and antipsychotics. PharmGKB and Sequence2Script support access to foundational literature and the clinical implementation of PGx results.PPC, ADP, APS"

Biomarker • Clinical • CNS Disorders • Psychiatry • CYP19A1 • CYP2C19 • HTR2A • SLC6A4

Antidepressants and Microscopic Colitis: A Propensity-Matched Comparison to Bupropion (ACG 2025) - "Other individual agents, including sertraline, fluoxetine, venlafaxine, and desvenlafaxine, were not significantly associated with MC compared to bupropion. After propensity score matching, ten antidepressant exposure groups (including SSRIs and SNRIs) were compared to bupropion for the development of microscopic colitis. Both SSRIs and SNRIs as medication classes were associated with significantly lower odds of developing microscopic colitis compared to bupropion (SSRI OR 0.68, 95% CI 0.54–0.86, p = 0.001; SNRI OR 0.64, 95% CI 0.50–0.81, p = 0.0002). Among individual agents, duloxetine (OR 0.79, 95% CI 0.45–0.77, p < 0.0001), escitalopram (OR 0.77, 95% CI 0.60–0.98, p = 0.04), and paroxetine (OR 0.66, 95% CI 0.45–0.97, p = 0.03) were also significantly associated with decreased odds."

Gastroenterology • Gastrointestinal Disorder • Immunology

Notorious GSK paroxetine adolescent depression trial is slapped with expression of concern amid legal action. (PubMed, BMJ) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Inner ear signs and symptoms induced by antidepressants: a disproportionality analysis based on the FAERS database. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The results suggest a significant association between antidepressants- such as duloxetine, paroxetine, bupropion, venlafaxine, sertraline, desvenlafaxine, escitalopram, and citalopram- and inner ear signs and symptoms. These symptoms may severely impact patients' quality of life and daily functioning, highlighting the need for clinicians to closely monitor patients for inner ear signs and symptoms when prescribing these medications."

Journal • Ataxia • Movement Disorders • Otorhinolaryngology • Vertigo